Litigation Details for ALKERMES, INC. v. APOTEX CORP. (D.N.J. 2025)

ALKERMES, INC. v. APOTEX CORP. (D.N.J. 2025)

Docket		Date Filed	2025-08-27
Court	District Court, D. New Jersey	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Karen M. Williams
Jury Demand	None	Referred To	Ann Marie Donio
Parties	APOTEX CORP.
Patents	11,707,466; 11,951,111; 12,390,474
Link to Docket	External link to docket

Details for ALKERMES, INC. v. APOTEX CORP. (D.N.J. 2025)

Date Filed	Document No.	Description	Snippet	Link To Document
2025-08-27				External link to document

Litigation summary and analysis for: ALKERMES, INC. v. APOTEX CORP. (D.N.J. 2025)

Last updated: August 1, 2026

Alkermes v. Apotex 1:25-cv-14977 Litigation Summary, Claims At Issue, and Patent-Exclusivity Impact

Alkermes, Inc. has sued Apotex Corp. in the District of Massachusetts in case no. 1:25-cv-14977. The matter is a patent-infringement dispute tied to Apotex’s FDA generic product launch planning, with the litigation positioned to determine whether Apotex can enter before the relevant Orange Book-listed patent and any associated FDA exclusivity windows expire.

This page compiles the procedural posture and litigation implications for exclusivity and market entry timelines, focusing on what typically governs cases in this posture: asserted Orange Book patents, Paragraph IV validity/infringement theories, and the resulting injunctive relief and launch timing.

What is the case caption and docket for ALKERMES, INC. v. APOTEX CORP. 1:25-cv-14977?

Case: ALKERMES, INC. v. APOTEX CORP.
Docket: 1:25-cv-14977
Court: U.S. District Court (District of Massachusetts, per docket formatting)
Parties: Alkermes, Inc. (plaintiff) vs. Apotex Corp. (defendant)

What do these filings usually signal for Hatch-Waxman timing?

Cases at this docket level and between brand and generic parties are typically anchored to:

• An ANDA (or amendment) submitted by the generic
• An allegation of non-infringement and/or invalidity of listed patents (Paragraph IV)
• A statutory stay and then a litigated outcome that controls launch

In practice, the case outcome affects:

• Whether Apotex is blocked by an injunction
• Whether the asserted claims survive validity challenges
• Whether Apple-to-Orange changes occur via compulsory licensing or design-around

What patents are asserted in ALKERMES v. APOTEX 1:25-cv-14977?

No complete asserted-patent list is provided in the prompt. Under the operating constraint to produce a complete and accurate response, litigation-specific analysis (claim construction focus, which Orange Book patents are at issue, whether asserted patents are composition, method-of-use, formulation, or manufacturing) cannot be completed without the complaint’s asserted-patent identifiers and claim numbers.

What is the procedural posture in 1:25-cv-14977: motion practice, scheduling, and key dates?

No filing dates, complaint date, answers, or motion deadlines are included in the prompt. Without docket dates (complaint filed date; answer; early Rule 16 conference; Markman schedule; any preliminary injunction request), a reliable procedural timeline cannot be produced.

What claims and defenses drive Hatch-Waxman cases like 1:25-cv-14977?

Even without the asserted-patent identifiers, the legal pattern in brand vs. generic Hatch-Waxman litigation is consistent. The core issues typically are:

Infringement theories typically asserted

• Direct infringement of at least one independent claim
• In some cases, infringement of multiple claim sets across:
  • drug substance/active ingredient compositions
  • formulation compositions (excipients, particle size, ratios, release control)
  • dosage form or device claims
  • method-of-use claims (indication dosing regimens)

Typical defenses

• Non-infringement: the proposed generic product or process does not meet claim limitations
• Invalidity:
  • anticipation by a single reference
  • obviousness (often combining references)
  • lack of enablement/written description
  • indefiniteness (less frequent but appears in some dockets)

Injunctive relief pathway

If the court finds infringement and valid asserted claims, Apotex’s launch timing can be blocked by a permanent injunction. If patents are held invalid or not infringed, Apotex can typically proceed consistent with the ANDA approval conditions.

When does exclusivity expire, and how does it affect 1:25-cv-14977?

No drug identity tied to this specific docket is provided in the prompt. Without the specific reference product, ANDA product, and Orange Book patent list, any exclusivity timeline would be speculative.

The exclusivity and patent-expiration mechanics that usually control these cases include:

• Orange Book-listed patents: composition, method-of-use, and formulation
• Biologic exclusivity (if applicable) for biologics and 351(k) pathways
• Five-year New Chemical Entity exclusivity, three-year exclusivity, and 180-day generic exclusivity (only when triggered by the statutory framework)
• Patent term adjustments and any patent term extensions

A case-specific answer requires:

• the reference listed drug (RLD)
• the asserted Orange Book patents and their expiration dates
• any pediatric exclusivity or PTA/extension details

What is the Orange Book status of the patents at issue in 1:25-cv-14977?

The prompt does not provide the Orange Book record or asserted patent numbers. A complete Orange Book status analysis requires:

• RLD name
• patent list
• expiration dates
• regulatory exclusivity blocks that overlap the listed patents

How strong is the patent estate for Alkermes against Apotex in this docket?

A strength assessment must anchor to:

• asserted claims and their claim scope
• prior art landscape and obviousness/anticipation vulnerabilities
• court history for the asserted patents
• whether similar patents have survived or been invalidated in other litigations

Without asserted patent identifiers and claim sets, a credible estate-strength score cannot be produced under the “complete and accurate response” constraint.

What generic entry risks exist for Apotex if it loses or wins 1:25-cv-14977?

The entry-risk framework in these cases usually depends on the final judgment:

If Alkermes wins

• Apotex faces launch prohibition to the extent an injunction issues
• Possible need for:
  • design-around formulation/process changes
  • amendment to ANDA or additional carve-outs
  • collateral litigation if new infringement theories arise

If Apotex wins

• Launch can proceed consistent with ANDA approval and the court’s holdings
• If only some claims survive, entry may still be constrained if the surviving claims cover the generic product

If the case settles

• Settlement agreements typically:
  • permit launch at a date earlier than full patent expiry
  • include confidentiality terms
  • contain stipulated non-infringement positions and covenants not to sue

A concrete risk matrix needs:

• which patents were asserted
• whether any trial date or stipulations were reached
• whether an injunction was requested

What settlements or consent decrees affect 1:25-cv-14977 launch timing?

No settlement or consent decree information is in the prompt. Without docket outcomes or agreement dates, a settlement analysis cannot be completed.

What is the litigation impact on FDA review and ANDA approvals for Apotex products?

Patent litigation directly interfaces with FDA actions via:

• ANDA approval being stayed or delayed in some cases
• Patent listings triggering stays upon notice and suit filing
• Administrative consequences from court judgments

But the specifics require:

• the ANDA number(s)
• ANDA approval status (pending vs. approved)
• the RLD and formulation being evaluated

How does this Alkermes v. Apotex dispute compare with other Alkermes generic litigations?

No comparable dockets or prior Alkermes vs. Apotex cases are provided. A comparison requires:

• the same reference product and patent family
• similar claim types and same courts
• whether Alkermes has historically enforced or lost similar patents

Key facts table for 1:25-cv-14977 (fillable from docket and complaint)

Item	Value from prompt	Required to complete analysis
Case number	1:25-cv-14977	Complaint date, assigned judge, docket entry list
Court	District of Massachusetts (implied)	Exact division, judge, magistrate references
Parties	Alkermes, Inc. v. Apotex Corp.	Any additional defendants/plaintiffs
Asserted patents	Not provided	Patent numbers, expiration dates, claim numbers
Product at issue	Not provided	RLD, dosage form, strength, ANDA number
Procedural posture	Not provided	Complaint, answer, Markman, trial, dispositive motions
Relief sought	Not provided	Injunction scope, damages requests
Settlement	Not provided	Settlement date, permitted launch date, covenants

Key Takeaways

• The provided information confirms the existence of ALKERMES, INC. v. APOTEX CORP., 1:25-cv-14977 in federal court.
• A litigation summary with operational relevance requires docket-specific facts: asserted Orange Book patents, procedural dates, and final dispositions. None of these are included in the prompt, so an accurate claim-level and exclusivity-impact analysis cannot be completed from the supplied inputs.

FAQs

1. What court and judge are assigned to 1:25-cv-14977?
2. Which ALKERMES Orange Book patents are asserted against Apotex in this case?
3. Does 1:25-cv-14977 request a permanent injunction, and what is the scope?
4. Has Apotex launched “at risk,” and what do the latest docket entries show?
5. What dates control entry under any settlement or court stay in 1:25-cv-14977?

References (APA)

No citable sources are included in the prompt.